Regeneron Pharmaceuticals Investor Presentation — May 2022

Document content

Regeneron Corporate Presentation

This non -promotional presentation is intended for the investor audience and contains investigational data as well as forward -looking statements; actual results may vary materiallyThis presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual

events orresults may differ materially from these forward -looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended to

identify such forward -looking statements, although notallforward -looking statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact ofSARS -

CoV-2(thevirus thathascaused theCOVID -19pandemic) onRegeneron's business anditsemployees, collaborators, andsuppliers andother third parties onwhich Regeneron relies, Regeneron's anditscollaborators’ ability

tocontinue toconduct research andclinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed orotherwise commercialized byRegeneron and/or itscollaborators orlicensees

(collectively, ”Regeneron’s Products“), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andproduct candidates being developed byRegeneron and/or its

collaborators orlicensees (collectively, “Regeneron’s Product Candidates”) andresearch andclinical programs now underway orplanned, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab),

Libtayo®(cemiplimab), Praluent®(alirocumab), Kevzara®(sarilumab ),EvkeezaTM(evinacumab ),Inmazeb®(atoltivimab ,maftivimab ,andodesivimab -ebgn ),REGEN -COV®(casirivimab andimdevimab ),fasinumab, garetosmab ,

pozelimab ,odronextamab, itepekimab ,fianlimab, REGN 5458 ,REGN 5713 -5714 -5715 ,REGN 1908 -1909 ,Regeneron’s and itscollaborators’ other oncology programs (including itscostimulatory bispecific portfolio),

Regeneron’s anditscollaborators’ earlier -stage programs, andtheuseofhuman genetics inRegeneron’s research programs ;safety issues resulting from theadministration ofRegeneron’s Products andRegeneron’s Product

Candidates inpatients, including serious complications orside effects inconnection with theuseofRegeneron’s Products andRegeneron’s Product Candidates inclinical trials ;thelikelihood, timing, andscope ofpossible

regulatory approval andcommercial launch ofRegeneron’s Product Candidates andnew indications forRegeneron’s Products, including without limitation those listed above ;thelikelihood andtiming ofachieving anyofthe